A lack of openness about designs and results of clinical trials, coupled with inadequate oversight of off-label use of drugs and adaverse events, puts consumers of health products at risk. There is also the aspect that government sponsored clinical trials are paid for by the public, yet they must purchase the information when results are published in medical journals. We should not have to pay twice for studies we've funded through NIH. Business has taken precedence over service.
